Aspen Neuroscience leverages stem cell biology and genomics for Parkinson's disease treatment. The self-described leading company aims to provide a personalized cell therapy to safely turn the clock back on Parkinson's disease.

Aspen Neuroscience

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

Iktos leverages AI and robotics to transform drug discovery, integrating generative AI with automated synthesis and testing to accelerate the development of new treatments.

Iktos

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Silicon Valley Bank

California Institute for Regenerative Medicine

Domain Associates

ARCH Venture Partners

Axon Ventures

OrbiMed

Frazier Healthcare Partners

Section 32 Sam Altman

EDBI

Frazier Life Sciences

Newton Investment Management

NS Investment

Google Ventures

Gaingels

LYFE Capital

Medical Excellence Capital

Mirae Asset Capital

Bioverge

Aspen Neuroscience, Inc.

This year Aspen participated in the Life Science Cares San Diego backpack drive to help ensure local underserved students start the year with all the school supplies they need for the upcoming school year.

We started with the goal of assembling 50 backpacks for our community. Our team far surpassed that goal with a total of 200 backpacks donated to Home Start Inc.! Thank you to our awesome team for donating supplies and helping us assemble these backpacks, which will allow all students in San Diego to succeed in school.

Also, a huge thank you to our rockstar team member Nayema Urdiales for organizing this drive!

We are thrilled to learn that Home Start Inc. has received 1,500 backpacks and school supplies to be donated to San Diego County students, beating their 1,200 backpack goal! We are delighted to have supported this effort!

The Journal of Neurosurgery has published online a study 
(https://lnkd.in/eNAiayGM) by Dr. Marina Emborg's lab at the Wisconsin National Primate Research Center at the University of Wisconsin-Madison regarding the novel cell transplantation approach being used for the delivery of ANPD001, an autologous, dopaminergic neuronal cell replacement we are investigating as a potential treatment for Parkinson’s Disease. 
 
The study published today was also incorporated into Aspen’s Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA), enabling the company to proceed with the current Phase 1/2a first-in-human clinical trial of ANPD001. 
 
“By the time of diagnosis, it is common for people with Parkinson’s to have lost the majority of dopaminergic neurons, leading to progressive loss of motor and neurological function,” explained Ed Wirth, MD, PhD, study co-author and Aspen’s chief medical officer. “To replace these lost cells, we must target a very specific area of the brain with a high degree of surgical precision. Using the latest advances in intraoperative MRI guided techniques, the patient’s new cells are transplanted, a few microliters at a time, to the exact area where they are most needed.”  

Click the link below to learn more: 

https://lnkd.in/eu68jWfB

#celltherapy #Parkinsonsdisease

We are delighted to share that Aspen Neuroscience's President and CEO, Damien McDevitt, PhD, will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum tomorrow, Tuesday, July 9 at 10:35am PT (1:35pm ET).

A live webcast of the fireside chat will be broadcast during the event. Viewers can watch the live webcast at https://lnkd.in/geHU-3t9. We hope to see you there!

https://lnkd.in/gbEcmQi2

#celltherapy #parkinsonsdisease #autologous #iPSCs

We are pleased to share that Aspen Neuroscience is utilizing the MRI-Guided ClearPoint Neuro, Inc., Navigation System for all patients enrolled in the recently launched ASPIRO Phase 1/2a clinical trial for transplantation of dopaminergic neuron precursor cells (DANPCs) in patients with Parkinson's Disease (PD). 
 
The ClearPoint System utilizes intraprocedural MR images to provide real-time navigational instruction for the neurosurgeon, and confirmation that the desired anatomical target has been reached with submillimetric accuracy. Combined with The SmartFlow® Cannula, which is less than 2 millimeters in diameter, this allows minimally-invasive delivery of therapeutic agents in a patient's brain.
 
To learn more, click the link below:

https://lnkd.in/eXpvQB8y

#celltherapy #iPSCs #Parkinsonsdisease #autologous

Yesterday, Aspen had four teams play in the Parkinson's Association of San Diego's annual golf tournament. Thank you to the Parkinson's Association for hosting, we can't wait to join again next year!

Today our Executive Director of Facilities and Engineering, Jeff Barbee, will be participating in the the CRB Life Sciences Symposium during the BIO International Convention with a terrific panel of experts. 

The panel will discuss navigating and leveraging recent changes in the life sciences industry, with an emphasis on conversations around macroeconomic conditions, ecosystem evolution, technological advancements, and equality & sustainability. 

If you are attending the conference, we hope to see you there!

These past few days were a tremendous forum for education, sharing and networking at the ISCT, International Society for Cell & Gene Therapy annual meeting. 
 
After Thursday's presentations at the Translation to Clinic Concurrent Session and Scientific Poster Sessions, Aspen Neuroscience continued our presentations on Saturday, with CTO Kim Raineri sharing "Manufacturing of Autologous iPSCs," at Manufacturing Considerations for Autologous and Allogeneic iPSC-derived Therapies & Opportunities for Cross-industry Alignment. Our CSO Xiaokui Zhang, PhD chaired the "Characterization of iPSC-derived Cell Therapies – Going in Depth" session with Director of Analytical Development, Daniel Fremgen, presenting "Characterization of Autologous iPSCs and Dopaminergic Neuron Precursor Cells for Parkinson’s Disease."
 
We are honored to be a part of this incredible event, which continues to grow and add value every year. Thank you again to the ISCT organizers!

#celltherapy #iPSCs #Parkinsonsdisease #autologous

The ISCT, International Society for Cell & Gene Therapy annual meeting has kicked off, and Aspen is happy to be sharing news and updates with our colleagues! Yesterday, our Chief Scientific Officer, Xiaokui Zhang, PhD, chaired an informative and thoughtful discussion at the “Translation to Clinic Concurrent Session” at the ISCT 2024 Translational Pathway Sessions, featuring session speakers Adrienne Farid, PhD, and Shigeto Shimmura, MD. Dr. Zhang also presented “Autologous iPSC-Derived, Neuron Replacement for Parkinson’s Disease.”
 
And at yesterday's poster sessions, our Director of Analytical Development, Daniel Fremgen, presented “Analytical Development Strategy for Dopaminergic Neuron Precursor Cell Replacement Therapy for Parkinson’s Disease."
 
Thank you to the organizers and to our session speakers! Next up are presentations this Saturday at the "iPSCs Signature Series: From Bench to Bedside" - hope to see you there!

#celltherapy #parkinsonsdisease #autologous #iPSCs

We are excited to share multiple presentations this week at the ISCT, International Society for Cell & Gene Therapy Annual Meeting! Presentations will highlight a Aspen’s autologous iPSC-derived approach for neuron replacement therapy in trial for Parkinson’s disease, manufacturing advances and machine learning genomic models. 

Today our Chief Scientific Officer, Xiaokui Zhang, PhD, will chair the “Translation to Clinic Concurrent Session” and present, “Autologous iPSC-Derived Neuron Replacement for Parkinson’s Disease.” 

Today at the scientific poster sessions, Aspen's Director of Analytical Development, Daniel Fremgen, will present “Analytical Development Strategy for Dopaminergic Neuron Precursor Cell Replacement Therapy for Parkinson’s Disease.”

This Saturday, during the iPSCs Signature Series: From Bench to Bedside, our Chief Technology Officer, Kim Raineri, will present "Manufacturing of Autologous iPSCs,” and Daniel Fremgen, will highlight "Characterization of Autologous iPSCs and Dopaminergic Neuron Precursor Cells for Parkinson’s Disease." 

Click the attached press release for more details. And if you're attending ISCT this week, please stop by and say hello to the Aspen team!

https://lnkd.in/g98gRbfr

#celltherapy #autologous #iPSC #parkinsonsdisease

Metric
Company Name	Aspen Neuroscience	Eterna Therapeutics Inc.	Iktos
Symbol		ERNA
MSH ID	COM:ASPENNEUROSCIENCE	COM:ETERNATX	COM:IKTOS
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Pharmaceuticals
Country	US	US	FR
Stage			Series A
Employee Count		8
Website	aspenneuroscience.com	brooklynitx.com	iktos.com
LinkedIn	aspen-neuroscience		iktos
Founders

Metric
Market Cap	9.90M
Enterprise Value
Monthly Web Traffic	270.57K	1.21K
Web Traffic Growth	0.55	-0.40
Valuation
Raised Capital		16.41M

Metric
Revenue		68K
Revenue (LTM)
Revenue (NTM)
Gross Profit		-1.29M
EBITDA		-19.55M
Operating Income		-20.67M
Net Income		-21.67M
EPS		-4.08
Diluted EPS		-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-5.88
Operating Profit Margin		-135.73
EBITDA Margin		-287.51
Net Profit Margin		-147.65
Return on Equity		15.58
Return on Assets		-0.44
Return on Capital Employed		-0.50

COM:ASPENNEUROSCIENCE

Aspen Neuroscience

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.42
P/B Ratio		2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		192.73
EV Multiple		2.09

Metric
Days Sales Outstanding		12.71K
Days Payables Outstanding		4.45K
Days Inventory Outstanding
Operating Cycle		2.28K
Cash Conversion Cycle		1.79K
Asset Turnover		0.00

Metric
Operating Cash Flow		-20.41M
Free Cash Flow		-20.43M
Cash Flow to Debt		-0.38
Operating Cash Flow/Sales		-101.81
Free Cash Flow Yield		-2.54

Metric
Cash & Equivalents		7.58M
Accounts Receivable		527K
Inventory
Goodwill		2.04M
Debt to Capitalization		2.84
Debt to Assets		0.79
Current Ratio		0.73
Quick Ratio		1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		28.90
R&D to Revenue		130.82
SG&A to Revenue		252.08